Innovent Acquires Rights to KRAS G12C Candidate in $312 Million Pact

Suzhou Innovent acquired greater China rights to GenFleet's lead KRAS G12C oncology candidate in a $312 million agreement. GenFleet is a Shanghai clinical-stage biotech focused on novel oncology and immunology targets. Innovent will pay $22 million upfront, invest $50 million in global development support (if Innovent exercises its global option), and make up to $240 million in milestone payments. GenFleet's KRAS G12C candidate, GFH925, was recently approved to start China trials in patients with cancers that have a KRAS G12C mutation. More details.... Stock Symbol: (HK: 01801) Share this with colleagues: // //